FDA Accepts Valnevas Chikungunya Vaccine License Application for Priority Review - Benzinga
| VLA Stock | EUR 1.89 0.12 5.97% |
About 61% of Valneva SE's investor base is looking to short. The analysis of current outlook of investing in Valneva SE suggests that many traders are alarmed regarding Valneva SE's prospects. The current market sentiment, together with Valneva SE's historical and current headlines, can help investors time the market. In addition, many technical investors use Valneva SE stock news signals to limit their universe of possible portfolio assets.
Valneva |
FDA Accepts Valnevas Chikungunya Vaccine License Application for Priority Review Benzinga
Read at news.google.com
 |
Valneva SE Fundamental Analysis
We analyze Valneva SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valneva SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valneva SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Valneva SE is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Valneva SE Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Valneva SE stock to make a market-neutral strategy. Peer analysis of Valneva SE could also be used in its relative valuation, which is a method of valuing Valneva SE by comparing valuation metrics with similar companies.
Peers
Valneva SE Related Equities
| DBV | DBV Technologies | 13.21 | ||||
| GNFT | Genfit | 2.93 | ||||
| NANO | Nanobiotix | 3.30 | ||||
| IPH | Innate Pharma | 6.54 | ||||
| VALN | Valneva SE | 6.98 |
Complementary Tools for Valneva Stock analysis
When running Valneva SE's price analysis, check to measure Valneva SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valneva SE is operating at the current time. Most of Valneva SE's value examination focuses on studying past and present price action to predict the probability of Valneva SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valneva SE's price. Additionally, you may evaluate how the addition of Valneva SE to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |